Bank of America’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank of America’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-23,300	Closed	-$3.64M	–	8010
2020 Q4	$3.64M	Hold	23,300	–	–	﹤0.01%	3427
2020 Q3	$2.67M	Sell	23,300 -2,000	-8%	-$216K	﹤0.01%	3454
2020 Q2	$2.84M	Sell	25,300 -20,000	-44%	-$2.12M	﹤0.01%	3345
2020 Q1	$4.07M	Buy	45,300 +8,900	+24%	+$873K	﹤0.01%	2856
2019 Q4	$3.94M	Sell	36,400 -94,200	-72%	-$10.1M	﹤0.01%	3457
2019 Q3	$12.8M	Buy	+130,600	New	+$14.7M	﹤0.01%	2257
2019 Q2	–	Sell	-8,500	Closed	-$1.15M	–	7542
2019 Q1	$1.15M	Sell	8,500 -20,900	-71%	-$2.6M	﹤0.01%	4416
2018 Q4	$2.86M	Sell	29,400 -500	-2%	-$59.1K	﹤0.01%	3543
2018 Q3	$4.16M	Sell	29,900 -50,600	-63%	-$6.35M	﹤0.01%	3363
2018 Q2	$9.99M	Sell	80,500 -407,100	-83%	-$47.6M	﹤0.01%	2467
2018 Q1	$54.3M	Buy	487,600 +441,200	+951%	+$52.7M	0.01%	1003
2017 Q4	$5.55M	Hold	46,400	–	–	﹤0.01%	3028
2017 Q3	$6.51M	Buy	46,400 +2,900	+7%	+$394K	﹤0.01%	2939
2017 Q2	$5.29M	Hold	43,500	–	–	﹤0.01%	2980
2017 Q1	$5.27M	Buy	43,500 +26,000	+149%	+$3.35M	﹤0.01%	2969
2016 Q4	$2.14M	Hold	17,500	–	–	﹤0.01%	3716
2016 Q3	$2.14M	Sell	17,500 -32,200	-65%	-$4.14M	﹤0.01%	3586
2016 Q2	$5.8M	Buy	49,700 +24,500	+97%	+$3.48M	﹤0.01%	2684
2016 Q1	$3.51M	Buy	+25,200	New	+$3.7M	﹤0.01%	3088
2015 Q3	–	Sell	-83,500	Closed	-$15.1M	–	7514
2015 Q2	$15.1M	Buy	83,500 +65,500	+364%	+$11.3M	﹤0.01%	1620
2015 Q1	$3.12M	Sell	18,000 -80,700	-82%	-$14.6M	﹤0.01%	2856
2014 Q4	$18.3M	Sell	98,700 -800	-0.8%	-$148K	0.01%	1453
2014 Q3	$16.5M	Sell	99,500 -28,700	-22%	-$4.71M	0.01%	1545
2014 Q2	$20M	Buy	128,200 +117,800	+1,133%	+$18.6M	0.01%	1406
2014 Q1	$1.58M	Sell	10,400 -70,800	-87%	-$11.3M	﹤0.01%	3433
2013 Q4	$10.8M	Sell	81,200 -16,700	-17%	-$2M	﹤0.01%	1789
2013 Q3	$11.4M	Buy	97,900 +90,400	+1,205%	+$9.92M	﹤0.01%	1676
2013 Q2	$692K	Buy	+7,500	New	+$723K	﹤0.01%	4425

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bank of America's ALXN Position: Q3 2021 in Review

Bank of America sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,429,070 shares — an estimated $263M sold.

Bank of America first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $507M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Bank of America reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bank of America sold 1,429,070 Alexion Pharmaceuticals shares in Q3 2021, an estimated $263M.
Bank of America first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Bank of America's Alexion Pharmaceuticals position peaked at $507M in Q4 2015.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank of America's 13F filing for Q3 2021, filed 15 Nov 2021.